U.S. markets open in 4 hours 50 minutes
  • S&P Futures

    4,332.50
    +17.75 (+0.41%)
     
  • Dow Futures

    33,982.00
    +107.00 (+0.32%)
     
  • Nasdaq Futures

    14,780.50
    +65.50 (+0.45%)
     
  • Russell 2000 Futures

    1,786.70
    +8.80 (+0.49%)
     
  • Crude Oil

    91.46
    +1.07 (+1.18%)
     
  • Gold

    1,914.20
    -5.60 (-0.29%)
     
  • Silver

    23.05
    -0.15 (-0.65%)
     
  • EUR/USD

    1.0567
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    4.5580
    0.0000 (0.00%)
     
  • Vix

    18.08
    -0.86 (-4.54%)
     
  • GBP/USD

    1.2158
    -0.0001 (-0.00%)
     
  • USD/JPY

    149.0060
    +0.0070 (+0.00%)
     
  • Bitcoin USD

    26,225.74
    -43.76 (-0.17%)
     
  • CMC Crypto 200

    561.57
    -2.24 (-0.40%)
     
  • FTSE 100

    7,641.88
    +16.16 (+0.21%)
     
  • Nikkei 225

    32,371.90
    +56.85 (+0.18%)
     

Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

CAMBRIDGE, Mass., February 02, 2023--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m. ET to review fourth quarter and full year 2022 financial results and discuss recent business updates.

The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201006095/en/

Contacts

Investor Contact
Helen Rubinstein
315-382-3979
helen.rubinstein@sagerx.com

Media Contact
Matthew Henson
917-930-7147
matthew.henson@sagerx.com